|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.07 USD | +2.59% |
|
+2.28% | +3.90% |
Oct 11 (Reuters) - Supernus Pharmaceuticals Inc said on Monday it would acquire drugmaker Adamas Pharmaceuticals Inc for about $400 million upfront, excluding contingent value rights worth about $50 million.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
| 1st Jan change | Capi. | |
|---|---|---|
| +3.90% | 1.6B | |
| +5.31% | 69.91B | |
| +10.97% | 9.03B | |
| -16.83% | 4.75B | |
| +43.48% | 4.31B | |
| +3.20% | 3.88B | |
| +18.82% | 2.37B | |
| -21.36% | 2.26B | |
| -29.67% | 2.2B | |
| +8.38% | 1.98B |
SUPERNUS PHARMACEUTICALS, INC. 
